Compare Bit Digital Inc (BTBT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bit Digital Inc vs Crispr Therapeutics AG — how do they compare? Bit Digital Inc trades at $1.48 (market cap $471.05M), while Crispr Therapeutics AG trades at $53.95 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 11.1× Bit Digital Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BTBT | CRSP | |
|---|---|---|
Market Cap | $471.05M | $5.23B |
Sector | Technology | Health |
52-Week High | $4.22 | $76.78 |
52-Week Low | $1.23 | $44.34 |
Enterprise Value | $760.36M | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.46, up 12.31% today, but the technical outlook is bearish with selling pressure outweighing buying signals. Fundamentally, the company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45% in 2026, indicating severe profitability challenges despite a gross margin above 55%. Recent earnings have missed expectations in two of the last three quarters.
The outlook remains challenged by persistent losses and negative cash flow from operations. While analyst coverage is limited and currently shows a 100% buy rating from two firms, significant execution risk and reliance on financing activities to offset operational cash burns present substantial headwinds for shareholder value appreciation in the near term.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
